This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1978;43(3-4):253-62.

doi: 10.1007/BF01246962.

L-deprenyl treatment of on-off phenomena in Parkinson's disease

U K Rinne, T Siirtola, V Sonninen

PMID: 745018
DOI: 10.1007/BF01246962

L-deprenyl treatment of on-off phenomena in Parkinson's disease

U K Rinne et al. J Neural Transm. 1978.

. 1978;43(3-4):253-62.

doi: 10.1007/BF01246962.

Authors

U K Rinne, T Siirtola, V Sonninen

PMID: 745018
DOI: 10.1007/BF01246962

No abstract available

PubMed Disclaimer

Similar articles

L-deprenyl in the treatment of Parkinson's disease.
Csanda E, Tárczy M, Takáts A, Mogyorós I, Köves A, Katona G. Csanda E, et al. J Neural Transm Suppl. 1983;19:283-90. J Neural Transm Suppl. 1983. PMID: 6421993
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Csanda E, Tárczy M, Takáts A. Csanda E, et al. J Neural Transm Suppl. 1986;22:247-52. J Neural Transm Suppl. 1986. PMID: 3097259
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Birkmayer W, Knoll J, Riederer P, Youdim MB. Birkmayer W, et al. Mod Probl Pharmacopsychiatry. 1983;19:170-6. doi: 10.1159/000407513. Mod Probl Pharmacopsychiatry. 1983. PMID: 6408405 No abstract available.
R-(-)-deprenyl and parkinsonism.
Yahr MD. Yahr MD. J Neural Transm Suppl. 1987;25:5-12. J Neural Transm Suppl. 1987. PMID: 3123605 Review.
Selegiline in the treatment of Parkinson's disease.
Heinonen EH, Rinne UK. Heinonen EH, et al. Acta Neurol Scand Suppl. 1989;126:103-11. doi: 10.1111/j.1600-0404.1989.tb01789.x. Acta Neurol Scand Suppl. 1989. PMID: 2515715 Review.

See all similar articles

Cited by

Clinical pharmacokinetics of anti-parkinsonian drugs.
Cedarbaum JM. Cedarbaum JM. Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002. Clin Pharmacokinet. 1987. PMID: 3311529 Review.
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH, Myllylä V. Heinonen EH, et al. Drug Saf. 1998 Jul;19(1):11-22. doi: 10.2165/00002018-199819010-00002. Drug Saf. 1998. PMID: 9673855 Review.
The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.
Hazelhoff B, De Vries JB, Dijkstra D, de Jong W, Horn AS. Hazelhoff B, et al. Naunyn Schmiedebergs Arch Pharmacol. 1985 Jul;330(1):50-8. doi: 10.1007/BF00586709. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 2413370
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Mizuno Y, Kondo T. Mizuno Y, et al. Drug Saf. 1997 May;16(5):289-94. doi: 10.2165/00002018-199716050-00001. Drug Saf. 1997. PMID: 9187529 Clinical Trial.
Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.
Fredriksson A, Archer T. Fredriksson A, et al. J Neural Transm Gen Sect. 1995;102(1):19-34. doi: 10.1007/BF01276562. J Neural Transm Gen Sect. 1995. PMID: 8785021

See all "Cited by" articles

References

1. Z Neurol. 1972;202(1):1-20 - PubMed
1. N Engl J Med. 1969 Feb 13;280(7):337-45 - PubMed
1. Life Sci (1962). 1963 Jul;(7):448-58 - PubMed
1. Nature. 1960 Jun 25;186:1050-1 - PubMed
1. Wien Klin Wochenschr. 1969 Sep 26;81(39):677-9 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer